Send to

Choose Destination
Trends Pharmacol Sci. 1995 Aug;16(8):270-5.

Novel dopamine receptors half a decade later.

Author information

Unité de Neurobiologie et Pharmacologie de l'INSERM, Centre Paul Broca, Paris, France.


Only half a decade ago, the effects of dopamine were all attributed to activation of two receptor subtypes, the D1 and D2, with opposing effects on adenylate cyclase, and for which apparently selective ligands were available. From the end of 1988, however, the application of homology cloning techniques starting from sequences of the seven transmembrane domain catecholamine receptors, particularly that of the D2 receptor, led to the identification of 'novel', previously uncharacterized dopamine receptors. In this article, Pierre Sokoloff and Jean-Charles Schwartz discuss the functional significance of such diversity, as well as the new therapeutic perspectives it offers.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center